ABSTRACT Introduction: Benign prostatic hyperplasia (BPH) is a progressive condition characterized by prostate enlargement accompanied by lower urinary tract symptoms (LUTS). Benign prostatic hyperplasia arises in the periurethral and transition zones of the prostatic gland and represents an inevitable phenomenon for the ageing male population. An estimated 75% of men>50 years of age have symptoms arising from benign prostatic hyperplasia, and 20-30% of men reaching 80 years of age require surgical intervention for the management of BPH. Prostate specific antigen (PSA) is a serine protease produced by the prostate epithelium and periurethral glands in male. Serum PSA elevation occurs as a result of disruption of normal prostatic architecture that allows PSA to diffuse into prostatic tissue and gain access to the circulation. Benign prostatic hyperplasia, prostatic carcinoma and prostatitis are three common diseases where PSA in the serum is raised. Aims and objectives: To evaluate the PSA level and To find out the relationship between serum PSA level and the volume of prostate in Benign hyperplasia of prostate. Material and Methods: This is a Hospital based prospective study which was conducted in the Department of Surgery at Nepalgunj Medical College Teaching Hospital, th th
INTRODUCTION
Benign prostatic hyperplasia (BPH) is a progressive condition characterized by prostate enlargement accompanied by lower urinary tract symptoms (LUTS). Benign prostatic hyperplasia arises in the periurethral and transition zones of the prostatic gland and represents an inevitable phenomenon for the ageing male population. Benign prostatic hyperplasia is uncommon before age 40, roughly 50% of men develop BPH-related symptoms around 50 years of age. The incidence of BPH increases by 10% per decade and reaches 80% at approximately 80 years of age. An estimated 75% of men >50 years of age have symptoms arising from benign prostatic hyperplasia, and 20-30% of men reaching 80 years of age require surgical 1 intervention for the management of BPH .BPH affects both glandular epithelium and connective tissue stroma to variable degrees in which adenosis, epitheliosis and stromal 2 proliferation are seen in differing proportions .
Prostate specific antigen (PSA) is a serine protease produced by the prostate epithelium and periurethral glands in male. Serum PSA elevation occurs as a result of disruption of normal prostatic architecture that allows PSA to diffuse into prostatic tissue and gain access to the circulation. This can occur in the setting of prostate disease and prostate manipulation (prostate massage, prostate biopsy). Benign prostatic hyperplasia, prostatic carcinoma and prostatitis are three common diseases 3 where PSA in the serum is raised .
Prostate volume (PV) varies widely throughout man's lifetime, and in the course of different prostatic diseases, including benign prostatic hyperplasia (BPH). Both PV and serum prostate-specific antigen (PSA) are key predictors of clinical progression and response to medical therapy in patients with BPH, thus helping to select the regimen for medical treatment (alpha-blockers, 5-alpha-reductase inhibitors (5-ARI), or their 4 combination .
In normal person, the serum concentration of PSA are proportional to the volume of prostatic epithelium, but the release of PSA from BPH is three fold that from the normal prostate and in carcinoma of prostate the release of PSA is thirty fold. PSA is elevated approximately 0.12ng/ml/g of BPH tissue. Thus, patients with enlarged glands due to BPH may 5, 6 have elevated PSA levels .
The ratio of PSA to gland volume is termed as PSA density. The positive predictive value of PSA density is slightly higher than the use of a PSA level >4 ng/ml in several series (30-40% versus 20-30%). Instead of adjusting the PSA to total prostate volume, some have advocated adjusting it to transition zone volume 6 (PSA transition zone density) .
The concept of PSA density (PSAD) has been described as, the PSA value (ng/ml) divided by the prostate volume (ml). PSA levels associated with a small prostate may have prostate cancer while the same value of PSA in a man with a large prostate may indicate BPH. It has been suggested that a PSAD greater than 0.15 is associated with 25% incidence of cancer, and a PSAD less than 0.10 is associated with 5% incidence of 7 cancer .
During the past two decades, the development of highly specialized ultrasound equipment has allowed the application of this imaging technique in the diagnosis, treatment and follows up of prostatic disease, particularly BPH. Transabdominal ultrasound measurement of prostate volume is consistent and correlated to transrectal prostate volume when the bladder volume is less than 400ml. The maximum prostatic protrusion occurs when bladder volume is between 100 and 200ml. It is thus recommended that the transabdominal ultrasound measurement of prostatic protrusion should be carried out at bladder volumes between 100 and 200 ml and should be avoided at the extremes of 8 bladder volumes .
There is paucity of data regarding reports of PSA level in Benign hypertrophy of prostate and its relationship with volume of prostate in Nepal particularly in this region of country. Therefore this study was conducted to estimate serum PSA level and its relationship with volume of prostate. 
MATERIAL AND METHODS

Grades of prostatic enlargement on DRE
Grading of prostate volume was categorized using the grading 
PSA ESTIMATION
Blood sample was drawn before prostatic manipulation, waited at least for 24 hrs. After the manipulation. 5 ml of venous blood was collected in blood collecting tube. Standing at room temperature, centrifuging, separating serum part. PSA was estimated by chemi luminescence immunosorbent assay (CLIA), a solid phase two-site immunoassay. Transabdominal ultrasound was used to measure prostatic volume at Radiology Department. Patients with minimal bladder volume of 100 to 200 ml were subjected to USG for near correct estimation of 10 prostate volume by USG .
Prostatic volume was measured using ellipsoid formula. Ellipsoid formula (V) = length x height x width x 0.52. (V = volume of prostate). PSAD was then calculated by PSA (ng/ml) 7 divided by prostatic volume (ml).
All patients included in the study underwent transurethral resection of prostate. Following surgery the tissue resected were sent for histopathological examination to confirm the diagnosis of BPH and to exclude those patients with prostatic carcinoma. Bivariate correlation and regression analysis was done by using SPSS 20.0 for windows. P value of <0.05 was taken as statistically significant.
RESULT
A total of 30 patients were included in the study. Age of patients ranged from 44-82 years with mean age of 63.9 years (SD±8.64). The distribution of patient according to age group is shown in Table I . relationship of age with PSA and prostate volume . however, a few workers observed a weak relationship of age 3, 4 with PSA and prostate volume.
The present study is the analysis to address the interrelationship among age, serum PSA and prostate volume in a small cohort of men without prostate cancer. This study involved serum PSA estimation using the same method, and all prostate volume measurements were done by TAUS, thus assuring good reproducibility of the results. The most important finding is that there is an age-dependent relationship between serum PSA and prostate volume. Knowing a patient's age and serum PSA allows clinicians to determine whether the patient has prostatic enlargement as well as the degree of enlargement with reasonable certainty.
Prostate volume (PV) is perhaps the most extensively studied risk factor for BPH progression. Men with a PV of ≥ 30 mL are more likely to have moderate-to-severe symptoms (3.5-fold increase), decreased flow rates (2.5-fold increase), and urine retention (three-to four-fold increase) than are men with a PV < 30 mL. So, PV information has become more and more important because the PV strongly predicts BPH-related morbidity such as acute urinary retention and the need for surgery. Because PV is strongly related to serum PSA in men with no evidence of prostate cancer, it was suggested that serum PSA can be used to estimate the degree of prostate enlargement accurately enough for it was a useful tool in 15 therapeutic decision making .
Generally, the typical method of measuring PV is Transrectal 16 ultrasound (TRUS) (Stravodimos et al., 2009 ). But, TRUS is relatively painful. Moreover, TRUS is also not cost-effective and routine evaluation of patients with BPH. In our setting, TRUS may not be available everywhere. Additionally, DRE is simple to perform and practical for estimating the PV, but it has been 15 revealed that DRE underestimates the real prostate size .
Roehrborn and associates have introduced the concept of PSA as a surrogate measurement for prostate volume in patients 13 with clinical BPH and LUTS . However, Partin et al. (1990) have suggested that serum PSA does not correlate with prostate 17 volume in BPH . This study also support a positive relationship between PSA and prostate volume (Table V) . There are evidence to suggest that a reasonable linear correlation exists not only in patients with LUTS and clinical BPH, but also in a large series of patients with histologically proven BPH. These data are comparable to recent correlations by Bosch et al. and others, between PSA and prostate volume noted in patients with clinical BPH and LUTS, with the correlation coefficient (r) 13, 18, 19 ranging from 0.37 to 0.58 .
The moderately positive correlation of PSA and prostate volume observed in this study may be due to the dissimilarities between the databases. While previous studies have examined only patients with clinically diagnosed BPH, This study represents patients with histologically proven BPH. The observation in present study is in conformity with findings of other worker indicating the prevalence of clinical BPH and LUTS 20 match the prevalence of histological BPH . The differences between histologically and clinically derived databases may indeed be explained by the diverse etiologies of LUTS in a given population.
Among many factors that contribute to prostate enlargement in BPH, the two most well known etiologic factors were aging 21 and androgen . Consistent with the theory that aging is an etiological factor of BPH, the observation made in this study showed a trend of increasing median PV with advancing age (Table VII) . This increasing PV with aging is accompanied with an increasing trend of PSA with age (Table VI) . This observation 12, 13, 14, 22, 23 is consistent with other studies . The correlation between age and PV in present study is the weakest (r=0.036) which was similar to the result of the study done by Mosli et al. 4 in Saudi men . Consistent with results from other studies, PSA was positively correlated with age in present study. However, the correlation is the weakest (r=0.12) compared with results 13, 14, 23, 24 from other studies .Similar weak correlation was found in 3, 4, 15 some of the studies done to correlate PSA and age . The difference may be attributed to a selection bias. The age of our patients was not evenly distributed across the age range; about 40% of the patients were aged between 60-69 years. The uneven age distribution may have accounted for the difference in statistical analysis. There is a possibility that if we had enrolled more patients who were older in age the correlation between age and PSA might have become significant. 13, 24 PSA has been suggested as an estimator for PV . This is supported by the fact that prostatic epithelial cells are responsible for circulating PSA, and several studies had 14, 22, 25 documented a positive correlation between PSA and PV . 13, 14, 23, 24 correlation coefficient between PSA and PV . The findings of this showed a similar but moderately positive correlation with a correlation coefficient of (r=0.679, p<0.01) ( Table V) . The corresponding studies had a similar study design. The recent study by Putra et al. in 2016 suggested that difference between the degree of correlation of age with PV and age with PSA is probably attributable to the ethnic or geographical factors that 26 may influence prostatic growth .
PSAD cut off value of 0.15 as reported by other workers was consistent with the result of this study. The indication of prostatic biopsy and chances of being malignancy beyond the 7, 27, 28 level of 0.15 as reported in the previous studies is similar to this study. Mean PSAD was 0.10 and no case had PSAD more than 0.15.
There is paucity of report from this part of Nepal showing the relationship between PSA and PV and we couldn't find any report to show the efficacy of PSA at predicting more precise PV in Nepalese man. Because of the ability to obtain more accurate estimates of the PV without the help of more expensive, invasive diagnostic evaluations, PSA would give a more reasonable contribution in the proper management of patients with BPH.
The present findings suggest that PSA is a good indicator of prostatic volume, but there appears to be a weak relation among Age with PSA and prostate volume. The results of the analyses presented here characterize the average prostate volume given PSA level and age based on the clinical trial population studied. Caution should be exercised in attempting to predict precisely an individual patient's prostate volume given his age and PSA because the error associated with the predicted prostate volume for an individual patient is greater than that associated with the predicted average prostate volume. In addition, PSA and prostate volume measurements vary appreciably with use of different measurement techniques, each with its own measurement error and variability, and there are inherent differences among clinical practice settings that also will increase the uncertainty of prediction for individual patients. The relationship may not be applicable to patients with different characteristics from those in the clinical trials, so that the graphs may not be appropriate for patient populations and clinical settings different from those studied. Nonetheless, these relationships are likely to be useful as an aid in approximating average prostate size for men with given levels of serum PSA and age. However, larger and multicentric studies is suggested which will give more useful result.
CONCLUSION
The mean PSA and prostate volume increased with advancing age, and the correlation between PSA and prostate volume estimated by TAUS in BPH as found to be statistically significant (p< 0.05). DRE underestimated the volume of prostate with a mean difference 21.97ml. The correlation of age of the patient with PSA and prostate volume are (r=0.128) and (r=0.036) respectively. The above value shows that both are statistically weekly positive but the association between age of patient and PSA seems to be higher in comparison to age of the patient and prostate volume.
